Drug targets in infections with Ebola and Marburg viruses.
The development of antiviral drugs for Ebola and Marburg viruses has been slow. To date, beyond supportive care, no effective treatments, prophylactic measures, therapies, or vaccines are approved to treat or prevent filovirus infections. In this review, we examine the current treatments available to administer care for filovirus infection, the potential therapeutic targets that can be used for filovirus drug development, and the various drug targeting techniques used against filoviruses.
Gene
Olinger G
OG
United States Army Medical Research Institute of Infectious Diseases, Division of Virology, Frederick, Maryland 21702-5011, USA.
Julia
Biggins E
BE
Vanessa
Melanson R
MR
Victoria
Wahl-Jensen
WJ
Thomas
Geisbert W
GW
Lisa
Hensley E
HE
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D029043:Ebolavirus / Q000187:drug effects*; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D006801:Humans; D007167:Immunotherapy; D008379:Marburg Virus Disease / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D029024:Marburgvirus / Q000187:drug effects*
D000998:Antiviral Agents